Florida Accounts for Nearly Half the Nation’s Confirmed Acute Hepatitis C Cases, CDC Data Show

Florida accounts for approximately 43% of all confirmed acute hepatitis C cases nationally as of the week ending September 12, 2026, with a year-to-date total of 1,018 confirmed cases out of 2,358 reported nationwide. This disproportionate share is noted relative to Florida's small percentage of the U.S. population. The state's overall hepatitis C prevalence rate from 2013-2016 was near the national average, with an estimated 151,000 residents living with the virus and nearly 700 related deaths recorded in 2023. Public health researchers attribute Florida's elevated case counts largely to injection drug use, particularly among younger adults, as the primary transmission driver. Furthermore, demographic data indicates that the majority of cases are concentrated among men aged 50 to 74. While Florida has a surveillance infrastructure, research suggests that true infection rates may be masked by uneven testing practices across socioeconomic and racial groups.

The disparity between Florida's high reported case volume and its population share points toward a systemic issue concerning surveillance equity rather than solely infection prevalence. The narrative pivots on the role of injection drug use as the primary driver, which connects regional public health crises to national trends like the opioid epidemic. However, the data simultaneously reveal that active surveillance infrastructure may inflate case counts; disparities in screening and testing across socioeconomic and racial lines suggest that the true burden of undiagnosed infection is likely higher than reported by NNDSS metrics alone. The demographic skew toward older men highlights historical exposure patterns, which complicates simple attribution to current drug use trends. The implication for human agency lies in recognizing that reporting mechanisms—whether they are driven by testing capacity or social access—filter the reality of the epidemic. What further data is needed to differentiate between genuine transmission spikes and differential surveillance capture across Florida's diverse populations? How do inequities in healthcare access create hidden reservoirs of undiagnosed infection?